Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin
2007

Combining TRAIL Antibodies with Cisplatin for Mesothelioma Treatment

Sample size: 13 publication 10 minutes Evidence: moderate

Author Information

Author(s): Belyanskaya Larisa L, Marti Thomas M, Hopkins-Donaldson Sally, Kurtz Stefanie, Felley-Bosco Emanuela, Stahel Rolf A

Primary Institution: University Hospital of Zürich

Hypothesis

Can the combination of TRAIL receptor antibodies and cisplatin enhance apoptosis in malignant mesothelioma cells?

Conclusion

The sequential administration of cisplatin followed by TRAIL receptor antibodies Mapatumumab or Lexatumumab may improve treatment outcomes for patients with malignant pleural mesothelioma.

Supporting Evidence

  • Nine out of thirteen mesothelioma cell lines were sensitive to TRAIL.
  • Cisplatin enhanced the effectiveness of TRAIL receptor antibodies in inducing apoptosis.
  • The combination treatment showed a significant increase in cell death compared to single-agent treatments.

Takeaway

This study found that using two special antibodies with a chemotherapy drug can help kill cancer cells better than using either one alone.

Methodology

The study compared the sensitivity of 13 malignant pleural mesothelioma cell lines to TRAIL and two TRAIL receptor antibodies, assessing their effects in combination with cisplatin.

Limitations

The study primarily focused on in vitro cell lines, which may not fully represent in vivo responses.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1476-4598-6-66

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication